Mycenax Biotech (4726) — Cash Flow Reinvestment Rate

Latest as of March 2025: 7.62x

Mycenax Biotech (4726) has a Cash Flow Reinvestment Rate of 7.62x as of March 2025, reinvesting NT$108.92 Million (capex NT$84.30 Million plus investments NT$-24.62 Million) from operating cash flow of NT$14.29 Million. See Mycenax Biotech (4726) FCF generation index to measure how efficiently the company converts operating cash flow to free cash.

Reinvestment Rate

7.62x

(Capex + Investments) / Operating CF

Total Reinvested

NT$108.92 Million

Capex + Investments

Operating Cash Flow

NT$14.29 Million

TWD

Capital Expenditures

NT$84.30 Million

TWD

Mycenax Biotech Cash Flow Reinvestment Rate (2020–2020)

Historical reinvestment intensity for Mycenax Biotech across 1 annual periods. For the full cash flow conversion analysis, see cash flow conversion of Mycenax Biotech.

Annual Cash Flow Reinvestment Rate for Mycenax Biotech (2020–2020)

Year-by-year capital reinvestment analysis for Mycenax Biotech. See 4726 FCF to total liabilities ratio to measure the company's free cash flow as a share of total liabilities.

Year	Reinvestment Rate	Total Reinvested (TWD)	Operating CF	Capex	YoY Change
2020	1.62x	NT$282.34 Million	NT$174.17 Million	NT$260.22 Million	—

Cash Flow Reinvestment Rate = (ABS(Capex) + ABS(Investments)) / Operating Cash Flow